AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

South China Morning Post - Sep 29, 2026

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...

Read full article

More News

Kick Connect
About Us

Kick Connect publishes a comprehensive overview of the latest news and theories on science & technology. We also report accurate news with a unique perspective on the world around us.